Multicenter Epidemiologic Study of Severe Community Acquired Pneumonia in China

Shanghai Jiao Tong University

Status: Unknown

Conditions: Community-acquired Pneumonia

Study type: Observational

Funder types: Other

Identifiers

NCT03728816

RJ2017NO186-1

Details and patient eligibility

About

This study is aimed to understand the clinical characteristics, etiology and resistance phenotype of major pathogens of SCAP in China through multicenter and prospective investigation. Thus to provide epidemiological basis for improving the SCAP diagnosis and treatment protocol suitable for China.

Full description

During the study period, all patients who are diagnosed with SCAP and meet the inclusion criteria in the participating unit should be enrolled in the study . At the end of the trial, each participating unit should complete at least 20 qualified cases, and all participating units should have a total of more than 300 qualified cases.

1. Learn about the etiology of SCAP in China.
2. Grasp the resistance phenotype and molecular epidemiology of major pathogens of SCAP in China.
3. Know the important clinical characteristics of SCAP in China, including age, basic diseases, length of hospital stay, length of stay in ICU, duration of mechanical ventilation, clinical manifestations, imaging findings, complications, mortality, etc.
4. Analyze and clarify the clinical risk factors of affecting SCAP mortality.
5. Understand the current situation of antibiotic treatment of SCAP in China.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >18 yeas;
• Diagnosis of CAP according to the diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Exclusion criteria

• Bronchiectasis;
• Active tuberculosis;
• Aspiration pneumonia or obstructive pneumonia;
• Hospitalized in 2 weeks;
• Hospitalized or ventilated ≥5 days;
• Severe immunosuppression patients;
• Irregular follow-up and lost follow-up;
• Withdraw from the study for any reason.

Trial design

300 participants in 1 patient group

SCAP groups

Description:

all the SCAP patients who meet the inclusion criteria